Zeus Launches PFX™ Platform and Introduces PFX Flex™ Sub-Lite-Wall™, Advancing the Future of Catheter Innovation
Polymer platform sets a new standard for catheter design with PTFE-like performance and expanded material flexibility ORANGEBURG, S.C., Jan. 29, 2026 /PRNewswire/ -- Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advance catheter innovation with a focus on performance, design flexibility,...
NEXTBIOMEDICAL Secures Health Canada Approval for Nexsphere-F™ in Musculoskeletal Pain Embolization
SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received approval from Health Canada. Nexsphere-F™ is a fast resorbable microsphere designed for musculoskeletal...
Lorikeet Launches Coach: The First AI That Tells You Why Your Support Metrics Move – And Fixes the Problem
Coach evaluates 100% of support conversations, diagnoses performance issues, and implements fixes SYDNEY, Jan. 29, 2026 /PRNewswire/ -- Lorikeet, the company that helps businesses create universal AI concierges for their customers, today announced the launch of Coach, an AI co-worker that partners with CX teams to help them understand their performance, diagnose why metrics changed, and automatically fix issues...
MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease
FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, enabling the company to initiate a Phase 2a clinical trial in patients with...
Spectrum Dynamics Medical Receives FDA 510(k) Clearance for Veritas.AI™, Its AI-Powered Noise Reduction Platform for VERITON-CT
SARASOTA, Fla., Jan. 29, 2026 /PRNewswire/ -- Spectrum Dynamics Medical, a global leader in digital nuclear medicine imaging solutions, today announced that it has received FDA 510(k) clearance for Veritas.AI™ Noise Reduction, its advanced artificial intelligence platform designed to significantly enhance image quality, diagnostic confidence, and operational efficiency on the VERITON-CT® digital SPECT/CT system. Veritas.AI...
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. Cross-sector discussions emphasized the need for bridging gaps between academic research, industrial development, and clinical applications. SHANGHAI, Jan. 29,...
Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackles the profound challenges of NUT carcinoma, a rare cancer known for diagnostic difficulty, limited treatments, and poor survival. The center is...
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of...
Singapore hosts its first Global Health Film Festival, spotlighting pandemic and planetary health
The two-evening programme on 27-28 January at The Ngee Ann Kongsi Auditorium at the SingHealth Duke-NUS campus convened clinicians, students, policymakers and partners to focus on the importance of outbreak preparedness and planetary health SINGAPORE, Jan. 29, 2026 /PRNewswire/ -- Singapore has hosted its first Global Health Film Festival, bringing together clinicians, students, policymakers and partners to examine some of the...
Ivonescimab Included in FirstWord Pharma’s “The Drugs That Will Shape 2026”
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026...
